{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:50:09Z","timestamp":1779213009059,"version":"3.51.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"name":"Intramural Research Program of the US National Cancer Institute"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Division of Cancer Prevention of the NCI"},{"name":"Division of Cancer Epidemiology and Genetics, NCI, NIH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Experimental and clinical studies have implicated certain chemokines and angiogenic cytokines in multiple myeloma (MM) pathogenesis. To investigate whether systemic concentrations of these markers are associated with future MM risk and progression from its precursor, monoclonal gammopathy of undetermined significance (MGUS), we conducted a prospective study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We measured concentrations of 45 immunologic and pro-angiogenic markers in sera from 241 MM case patients, 441 participants with nonprogressing MGUS, and 258 MGUS-free control participants using Luminex-based multiplex assays and enzyme-linked immunosorbent assays. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression. We also evaluated absolute risk of progression using weighted Kaplan-Meier estimates. All statistical tests were two-sided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prediagnostic levels of six markers were statistically significantly elevated among MM case patients compared with MGUS-free control participants using a false discovery rate of 10% (EGF, HGF, Ang-2, CXCL12, CCL8, and BMP-9). Of these, three angiogenesis markers were associated with future progression from MGUS to MM: EGF (fourth vs first quartile: OR\u2009=\u20093.01, 95% CI = 1.61 to 5.63, Ptrend = .00028), HGF (OR = 2.59, 95% CI = 1.33 to 5.03, Ptrend = .015), and Ang-2 (OR = 2.14, 95% CI = 1.15 to 3.98, Ptrend = .07). A composite angiogenesis biomarker score substantially stratified risk of MGUS progression to MM beyond established risk factors for progression, particularly during the first 5\u2009years of follow-up (areas under the curve of 0.71 and 0.64 with and without the angiogenesis marker score, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our prospective findings provide new insights into mechanisms involved in MM development and suggest that systemic angiogenesis markers could potentially improve risk stratification models for MGUS patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jncics\/pkz104","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T20:10:19Z","timestamp":1576181419000},"source":"Crossref","is-referenced-by-count":15,"title":["A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-5812","authenticated-orcid":false,"given":"Jonathan N","family":"Hofmann","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-4820","authenticated-orcid":false,"given":"Rebecca","family":"Landy","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy J","family":"Kemp","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Santo","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene M","family":"McShane","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen\u2019s University, Belfast, Northern Ireland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-7428","authenticated-orcid":false,"given":"Joseph J","family":"Shearer","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Lan","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Rothman","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia A","family":"Pinto","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-2363","authenticated-orcid":false,"given":"Allan","family":"Hildesheim","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hormuzd A","family":"Katki","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1177-3108","authenticated-orcid":false,"given":"Mark P","family":"Purdue","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"2021010111095420100_pkz104-B1","volume-title":"Cancer Facts & Figures 2019","year":"2019"},{"issue":"6","key":"2021010111095420100_pkz104-B2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2021010111095420100_pkz104-B3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2021010111095420100_pkz104-B4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"9727","key":"2021010111095420100_pkz104-B5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"2021010111095420100_pkz104-B6","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2010.1713","article-title":"Multiple myeloma precursor disease","volume":"304","author":"Landgren","year":"2010","journal-title":"JAMA"},{"issue":"17","key":"2021010111095420100_pkz104-B7","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"9119","key":"2021010111095420100_pkz104-B8","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(97)09028-4","article-title":"Spectrum of AIDS-associated malignant disorders","volume":"351","author":"Goedert","year":"1998","journal-title":"Lancet"},{"issue":"9581","key":"2021010111095420100_pkz104-B9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"2021010111095420100_pkz104-B10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1055-9965.EPI-09-1220","article-title":"Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients","volume":"19","author":"Quinlan","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2021010111095420100_pkz104-B11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp Hematol"},{"issue":"4","key":"2021010111095420100_pkz104-B12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2021010111095420100_pkz104-B13","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","article-title":"Angiogenesis in multiple myeloma","volume":"42","author":"Jakob","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"2021010111095420100_pkz104-B14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"104","author":"Kumar","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2021010111095420100_pkz104-B15","doi-asserted-by":"crossref","first-page":"349S","DOI":"10.1016\/S0197-2456(00)00101-X","article-title":"Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial","volume":"21","author":"Hayes","year":"2000","journal-title":"Control Clin Trials"},{"issue":"9","key":"2021010111095420100_pkz104-B16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"2021010111095420100_pkz104-B17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"2021010111095420100_pkz104-B18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ypmed.2018.02.013","article-title":"A novel metric that quantifies risk stratification for evaluating diagnostic tests: the example of evaluating cervical-cancer screening tests across populations","volume":"110(May","author":"Katki","year":"2018","journal-title":"Prev Med"},{"issue":"6","key":"2021010111095420100_pkz104-B19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/ijc.31536","article-title":"Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: univariate and functionally informed multivariate analyses","volume":"143","author":"Vermeulen","year":"2018","journal-title":"Int J Cancer"},{"key":"2021010111095420100_pkz104-B20","article-title":"Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated prediagnostic blood samples","author":"Spath","year":"2464","journal-title":"Haematologica"},{"issue":"3","key":"2021010111095420100_pkz104-B21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"issue":"2","key":"2021010111095420100_pkz104-B22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","article-title":"Bone marrow angiogenesis in multiple myeloma","volume":"20","author":"Vacca","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2021010111095420100_pkz104-B23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.leu.2404402","article-title":"The history of the angiogenic switch concept","volume":"21","author":"Ribatti","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"2021010111095420100_pkz104-B24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"6","key":"2021010111095420100_pkz104-B25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/07357907.2013.800093","article-title":"Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma","volume":"31","author":"Pappa","year":"2013","journal-title":"Cancer Investig"},{"issue":"3","key":"2021010111095420100_pkz104-B26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","article-title":"Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group","volume":"91","author":"Seidel","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2021010111095420100_pkz104-B27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-018-0691-4","article-title":"Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial","volume":"12","author":"Saltarella","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2021010111095420100_pkz104-B28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1471-2407-10-198","article-title":"Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays","volume":"10","author":"Mahtouk","year":"2010","journal-title":"BMC Cancer"},{"issue":"10","key":"2021010111095420100_pkz104-B29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","article-title":"The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients","volume":"38","author":"Cao","year":"2010","journal-title":"Exp Hematol"},{"key":"2021010111095420100_pkz104-B30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.scr.2017.08.012","article-title":"Epidermal growth factor as a mechanosensitizer in human bone marrow stromal cells","volume":"24(Oct","author":"Muller-Deubert","year":"2017","journal-title":"Stem Cell Res"},{"issue":"2","key":"2021010111095420100_pkz104-B31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02983377","article-title":"Survival and proliferation factors of normal and malignant plasma cells","volume":"78","author":"Klein","year":"2003","journal-title":"Int J Hematol"},{"issue":"2","key":"2021010111095420100_pkz104-B32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2013.268","article-title":"Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial","volume":"28","author":"Bhutani","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2021010111095420100_pkz104-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2014.10.017","article-title":"Angiopoietin-2 in bone marrow milieu promotes multiple myeloma-associated angiogenesis","volume":"330","author":"Belloni","year":"2015","journal-title":"Exp Cell Res"},{"issue":"4","key":"2021010111095420100_pkz104-B34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0272989X0002000410","article-title":"Determining the area under the ROC curve for a binary diagnostic test","volume":"20","author":"Cantor","year":"2000","journal-title":"Med Decis Making"},{"issue":"7","key":"2021010111095420100_pkz104-B35","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2021010111095420100_pkz104-B36","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cam4.455","article-title":"Circulating TGF-beta1 and VEGF and risk of cancer among liver transplant recipients","volume":"4","author":"Engels","year":"2015","journal-title":"Cancer Med"},{"issue":"1","key":"2021010111095420100_pkz104-B37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","article-title":"Targeting SDF-1 in multiple myeloma tumor microenvironment","volume":"380","author":"Bouyssou","year":"2016","journal-title":"Cancer Lett"},{"issue":"6","key":"2021010111095420100_pkz104-B38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bjc.6600833","article-title":"Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3","volume":"88","author":"Vande Broek","year":"2003","journal-title":"Br J Cancer"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkz104\/31546763\/pkz104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/4\/2\/pkz104\/35335753\/pkz104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/4\/2\/pkz104\/35335753\/pkz104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:49:34Z","timestamp":1722178174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkz104\/5678799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkz104","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,12,16]]},"article-number":"pkz104"}}